UNB :
Developers of Sputnik V Covid-19 vaccine on Thursday called on British-Swedish pharmaceutical company AstraZeneca to try combining its experimental shot with the Russian one to boost efficacy.
“Current full dose AstraZeneca regimen resulted in 62% efficacy. If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the Sputnik V human adenoviral vector shot to boost efficacy,” the developers tweeted.
“Combining vaccine may prove important for revaccinations.”
AstraZeneca is going to run more trials to assess the efficacy of its vaccine after questions were raised over the results from its late-stage study, the company’s chief executive officer Pascal Soriot said.
Clinical trials of the Oxford vaccine were conducted on 20,000 volunteers
from the UK and Brazil. Preliminary results showed that the average vaccine efficacy was 70%.
During the trials, it was found that when two equally large doses of the vaccine were administered with a difference in a month, the level of protection against infection was 62%.
It increased to 90% when the subjects first received a small dose, and then, with a second injection, a bigger dose of the medicine, reports Tass.
According to the World Health Organization, there are about 170 projects in the world now to develop a vaccine against Covid-19.
On August 11, Russia was the first in the world to register a Covid-19 vaccine called Sputnik V. According to the Russian Direct Investment Fund, the efficacy of the vaccine is 95%.
Developers of Sputnik V Covid-19 vaccine on Thursday called on British-Swedish pharmaceutical company AstraZeneca to try combining its experimental shot with the Russian one to boost efficacy.
“Current full dose AstraZeneca regimen resulted in 62% efficacy. If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the Sputnik V human adenoviral vector shot to boost efficacy,” the developers tweeted.
“Combining vaccine may prove important for revaccinations.”
AstraZeneca is going to run more trials to assess the efficacy of its vaccine after questions were raised over the results from its late-stage study, the company’s chief executive officer Pascal Soriot said.
Clinical trials of the Oxford vaccine were conducted on 20,000 volunteers
from the UK and Brazil. Preliminary results showed that the average vaccine efficacy was 70%.
During the trials, it was found that when two equally large doses of the vaccine were administered with a difference in a month, the level of protection against infection was 62%.
It increased to 90% when the subjects first received a small dose, and then, with a second injection, a bigger dose of the medicine, reports Tass.
According to the World Health Organization, there are about 170 projects in the world now to develop a vaccine against Covid-19.
On August 11, Russia was the first in the world to register a Covid-19 vaccine called Sputnik V. According to the Russian Direct Investment Fund, the efficacy of the vaccine is 95%.
